AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its ...

India's Department of Pharmaceuticals found AbbVie Healthcare India sponsored ₹1.91 crore in international trips for 30 ...

The latest report, Panic Attack Treatment Global Market Report 2025, brings light to the rapid growth of panic attack treatment market in recent years. The market size is expected to surge from $3.04 ...

Analysis revealed that patients with T-cell exhausted archetype tumors had significantly higher rates of progressive disease ...

A study published in The BMJ compares the evidence around intermittent fasting and calorie restriction for weight loss. Prof Maik Pietzner, Chair in Health Data Modelling, Queen Mary University of ...

AbbVie Golden Ticket Comes to a ClosePress release2025-06-18 11:48AbbVie Golden Ticket ceremony at SmiLe Venture Hub.Lund, Sweden – The one-year AbbVie Golden Ticket program has officially concluded – ...

AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications ...

The protein expression market is primarily driven by the increasing prevalence of chronic diseases, which in turn fuels greater demand for biopharmaceuticals, including monoclonal antibodies and ...

The global biosimilar and biologics market is projected to grow from USD 561.7 billion in 2025 to USD 1,157.4 billion by 2035 ...

AbbVie’s migraine drug Atogepant just cleared a major Phase 3 hurdle, and it’s got Wall Street rubbing its temples—in ...